Angiotensin-II receptor blockers: Benefits beyond blood pressure reduction?

Journal of Human Hypertension

Volumn 19, Issue 5, 2005, Pages 331-339

  Volpe, M ^a,f   Ruilope, L M ^b   McInnes, G T ^c   Waeber, B ^d   Weber, M A ^e  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e STATE UNIVERSITY OF NEW YORK   (United States)

^f IRCCS NEUROMED   (Italy)

Author keywords

Angiotensin II receptor blockers; Antihypertensive therapy; Blood pressure; Cardiovascular risk

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; PLACEBO; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; COUGHING; DATA ANALYSIS; DIABETES MELLITUS; DISEASE PREDISPOSITION; DISEASE SEVERITY; DIZZINESS; DRUG CLASSIFICATION; DRUG ERUPTION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY DISEASE; MICROALBUMINURIA; MORBIDITY; PATIENT COMPLIANCE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; TASTE DISORDER;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD PRESSURE; HUMANS; HYPERTENSION; RISK FACTORS; TREATMENT OUTCOME;

EID: 18644365347     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001831     Document Type: Review

References (47)

1. Lewington S et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
2. Isles CG et al. Mortality in patients of the Glasgow Blood Pressure Clinic. J Hypertens 1986; 4: 141-156.
3. Hansson L et al for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
4. Andersson OK et al. Survival in treated hypertension: follow up study after two decades. Br Med J 1998; 317: 167-171.
5. Blood Pressure Lowering Treatment Trialists' Collaboration. Effect of angiotensin-converting enzyme inhibitors, calcium antagonists, and other blood pressure lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 355: 1955-1964.
6. Yusuf S et al for the Hearth Outcomes Prevention Evaluation (HOPE) Study Group. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. New Engl J Med 2000; 342: 145-153.
7. PROGRESS Collaborative Group. Randomized trial of perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.
8. Dahlof B et al for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For End-point reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
9. Lewis EJ et al for the IDNT Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851-860.
10. Brenner BM et al for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12): 861-869.
11. Ruilope LM, Coca A, Volpe M, Waeber B. ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations? Am J Hypertens 2002; 15: 367-371.
12. Alderman MH et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324(16): 1098-1104.
13. Chobanian A et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA 2003; 289: 2560-2571.
14. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertension 2003; 21: 1011-1053.
15. Burt VL et al. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26: 60-69.
16. Primatesta P, Brookes M, Poulter NR. Improved hypertension management and control: results from the health survey for England 1998. Hypertension 2001; 38: 827-832.
17. Volpe M et al. Beyond hypertension: towards guidelines for cardiovascular risk reduction. Am J Hypertens 2004; 17(11 Part 1): 1068-1074.
18. Lip GY, Beevers DG. More evidence on blocking the renin-angiotensin-aldosterone system in cardiovascular disease and the long-term treatment of hypertension: data from recent clinical trials (CHARM, EUROPA, Val-HeFT, HOPE and SYST-EUR). J Hum Hypertens 2003; 17: 747-750.
19. Timmermans PB. Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol 1999; 15(Suppl F): 26F-28F.
20. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998; 20: 671-681.
21. Moriwaki H et al. Losartan, an angiotensin II (AT1) receptor antagonist, preserves cerebral blood flow in hypertensive patients with a history of stroke. J Hum Hypertens 2004; 18(10): 693-699.
22. Julius S et al for the VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022-2031.
23. Benz JR et al. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12(12): 861-866.
24. Mallion JM et al. Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Blood Press Monit 1997; 2(4): 179-184.
25. Parving HH et al for the Irbesartan in Patients with type 2 Diabetes Microalbuminuria (IRMA2) Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
26. Alderman MH et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-1104.
27. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000; 355: 637-645.
28. Volpe M et al. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J Hypertens 2003; 21: 1429-1443.
29. Kjeldsen SE et al LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002; 288(12): 1491-1498.
30. Lindholm LH et al for the LIFE study group. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003; 362(9384): 619-620.
31. Weber MA et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004; 363(9426): 2049-2051.
32. Julius S et al VALUE Trial. VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003; 16(7): 544-548.
33. ALLHAT Officers Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
34. Hansson L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616.
35. Alderman MH, Cohen HW, Sealey JE, Laragh JH. Plasma renin activity levels in hypertensive persons: their wide range and lack of suppression in diabetic and in most elderly patients. Am J Hypertens 2004; 17(1): 1-7.
36. Verdecchia P et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43(5): 963-969.
37. Sharma AM et al. Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension 2002; 40(5): 609-611.
38. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 2004; 286(5): H1597-H1602.
39. Viberti G et al for the MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus. A blood pressure-independent effect. Circulation 2002; 106: 672-678.
40. Ibsen H et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22(9): 1805-1811.
41. Cohn JN et al for the Valsartan Heart Failure Trial Investigators. A randomized trial of the Angiotensin II Receptor Blocker Valsartan in Congestive Heart Failure (Val-HeFT). N Engl J Med 2001; 345: 1667-1675.
42. Granger CB et al for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-alternative trial. Lancet 2003; 362: 772-776.
43. McMurray JJ et al for the CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767-771.
44. Yusuf S et al for the CHARM Investigators and Committees. CHARM-Preserved Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003; 362(9386): 777-781.
45. Pfeffer MA et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet 2003; 362: 759-766.
46. Pfeffer MA et al for the Valsartan in Acute Myocardial Infarction Trial Investigators (VALIANT). Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906.
47. Weber MA et al. Quality of life measured in a practice-based hypertension trial of an angiotensin receptor blocker. J Clin Hypertens (Greenwich) 2003; 5: 322-329.